JP2020531543A - アマンタジン組成物、その調製、および使用方法 - Google Patents

アマンタジン組成物、その調製、および使用方法 Download PDF

Info

Publication number
JP2020531543A
JP2020531543A JP2020511528A JP2020511528A JP2020531543A JP 2020531543 A JP2020531543 A JP 2020531543A JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020531543 A JP2020531543 A JP 2020531543A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
amantadine
oral pharmaceutical
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531543A5 (https=
Inventor
グレゴリー ティー． ウェント，
グレゴリー ティー． ウェント，
ティモシー ジェイ． フルツ，
ティモシー ジェイ． フルツ，
サンギタ ゴーシュ，
サンギタ ゴーシュ，
ナタリー マクルーア，
ナタリー マクルーア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharma LLC
Original Assignee
Adamas Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharma LLC filed Critical Adamas Pharma LLC
Publication of JP2020531543A publication Critical patent/JP2020531543A/ja
Publication of JP2020531543A5 publication Critical patent/JP2020531543A5/ja
Priority to JP2022183927A priority Critical patent/JP2023009251A/ja
Priority to JP2024139596A priority patent/JP2024159885A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2020511528A 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法 Pending JP2020531543A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183927A JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549921P 2017-08-24 2017-08-24
US62/549,921 2017-08-24
PCT/US2018/047754 WO2019040748A1 (en) 2017-08-24 2018-08-23 AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183927A Division JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法

Publications (2)

Publication Number Publication Date
JP2020531543A true JP2020531543A (ja) 2020-11-05
JP2020531543A5 JP2020531543A5 (https=) 2021-09-24

Family

ID=65439620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511528A Pending JP2020531543A (ja) 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Country Status (10)

Country Link
US (3) US11077073B2 (https=)
EP (1) EP3672581A4 (https=)
JP (3) JP2020531543A (https=)
CN (2) CN111372578A (https=)
AU (2) AU2018320946B2 (https=)
BR (1) BR112020003375A2 (https=)
CA (1) CA3072764A1 (https=)
IL (1) IL272834B2 (https=)
MX (2) MX2020002078A (https=)
WO (1) WO2019040748A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US11441653B1 (en) 2021-05-20 2022-09-13 Dana Automotive Systems Group, Llc Integrated gearbox in electric motor systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512919A (ja) * 2009-12-02 2013-04-18 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
WO2014204933A1 (en) * 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JP2623099B2 (ja) 1987-11-06 1997-06-25 株式会社ニフコ スライダの引込み装置
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
NZ527832A (en) 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
IL159853A0 (en) 2001-07-17 2004-06-20 Teva Pharma Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20030045577A1 (en) 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
WO2003101458A1 (en) 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2003260336C1 (en) 2002-07-29 2008-05-29 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
KR100777904B1 (ko) 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
EA200600598A1 (ru) 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
AU2004273958A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
CN1870984A (zh) 2003-10-22 2006-11-29 莫茨药物股份两合公司 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005072125A2 (en) 2004-01-16 2005-08-11 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
CA2556214A1 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CA2569015A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
JP2006079138A (ja) 2004-09-07 2006-03-23 Ricoh Co Ltd ステータス取得方法、プリンタドライバ及び情報処理装置
US20190008799A1 (en) 2004-11-23 2019-01-10 Adamas Pharma, Llc Composition for administering an nmda receptor antagonist to a subject
EP1827385B1 (en) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20190328684A1 (en) 2004-11-24 2019-10-31 Adamas Pharma, Llc Composition and method for treating neurological disease
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) * 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US20080279819A1 (en) 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
WO2007056424A2 (en) 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
KR101575679B1 (ko) 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
US8779090B2 (en) * 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CA2689101C (en) 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US8247438B2 (en) * 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
AU2009281537A1 (en) 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
SI2408436T1 (sl) 2009-03-18 2017-06-30 Evonik Roehm Gmbh Farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola, ki uporablja oplaščenje, ki vsebuje nevtralne vinil polimere in ekscipiente
CA2756386C (en) 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
WO2010115015A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US8895662B2 (en) 2010-12-31 2014-11-25 Eternal Chemical Co., Ltd. Curable composition and method for manufacturing the same
US20130236544A1 (en) * 2012-03-08 2013-09-12 Dr. Reddy's Laboratories Ltd. Stable pharmaceutical compositions of fesoterodine
GB201516037D0 (en) 2015-09-10 2015-10-28 Agco Int Gmbh Vehicle axel assembly
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512919A (ja) * 2009-12-02 2013-04-18 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
WO2014204933A1 (en) * 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions

Also Published As

Publication number Publication date
IL272834A (en) 2020-04-30
AU2018320946B2 (en) 2024-05-02
IL272834B1 (en) 2024-04-01
CA3072764A1 (en) 2019-02-28
MX2020002078A (es) 2020-09-21
US12233033B2 (en) 2025-02-25
US20200069614A1 (en) 2020-03-05
BR112020003375A2 (pt) 2020-08-25
US11077073B2 (en) 2021-08-03
CN111372578A (zh) 2020-07-03
JP2024159885A (ja) 2024-11-08
EP3672581A4 (en) 2021-05-19
US11065213B2 (en) 2021-07-20
CN117860718A (zh) 2024-04-12
AU2018320946A1 (en) 2020-04-16
IL272834B2 (en) 2024-08-01
MX2023012198A (es) 2023-10-25
WO2019040748A1 (en) 2019-02-28
EP3672581A1 (en) 2020-07-01
JP2023009251A (ja) 2023-01-19
AU2024205201A1 (en) 2024-08-15
US20220117914A1 (en) 2022-04-21
US20190262285A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US12233033B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP6316376B2 (ja) アマンタジン組成物および使用方法
US11903908B2 (en) Methods of administering amantadine
JP6735020B2 (ja) アマンタジン組成物を投与する方法
CN110151731A (zh) 用于治疗注意力缺陷障碍的方法和组合物
US8747895B2 (en) Orally disintegrating tablets of atomoxetine
JP2026062756A (ja) ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
CN120417891A (zh) Irak4降解剂及其用途
KR101761983B1 (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
CN104220064B (zh) 一种含辛弗林和托吡酯的联合产品
CN101330913A (zh) 依他普仑的修饰和脉冲释放药物制剂
JP2021508316A (ja) サフィナミドを含む医薬組成物
US10894023B2 (en) Oral pH independent dosage formulation for treating neurodegenerative disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230301